vs
Ameris Bancorp（ABCB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Ameris Bancorp的季度营收约是Orthofix Medical Inc.的1.4倍（$314.4M vs $219.9M），Ameris Bancorp净利率更高（35.1% vs -1.0%，领先36.2%），Ameris Bancorp同比增速更快（10.0% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.3%）
Ameris Bancorp是总部位于美国佐治亚州亚特兰大的银行控股企业，旗下子公司Ameris Bank在佐治亚、阿拉巴马、佛罗里达、北卡罗来纳、南卡罗来纳五州运营全服务网点，另在多州设有抵押贷款专属站点，同时面向个人及企业客户提供便捷的线上及移动银行服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ABCB vs OFIX — 直观对比
营收规模更大
ABCB
是对方的1.4倍
$219.9M
营收增速更快
ABCB
高出8.0%
2.0%
净利率更高
ABCB
高出36.2%
-1.0%
两年增速更快
OFIX
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $314.4M | $219.9M |
| 净利润 | $110.5M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 35.1% | -1.0% |
| 营收同比 | 10.0% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $1.63 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABCBOFIX
| Q1 26 | $314.4M | — | ||
| Q4 25 | $307.1M | $219.9M | ||
| Q3 25 | $314.2M | $205.6M | ||
| Q2 25 | $300.7M | $203.1M | ||
| Q1 25 | $285.9M | $193.6M | ||
| Q4 24 | $290.8M | $215.7M | ||
| Q3 24 | $283.8M | $196.6M | ||
| Q2 24 | $300.6M | $198.6M |
净利润ABCBOFIX
| Q1 26 | $110.5M | — | ||
| Q4 25 | $108.4M | $-2.2M | ||
| Q3 25 | $106.0M | $-22.8M | ||
| Q2 25 | $109.8M | $-14.1M | ||
| Q1 25 | $87.9M | $-53.1M | ||
| Q4 24 | $94.4M | $-29.1M | ||
| Q3 24 | $99.2M | $-27.4M | ||
| Q2 24 | $90.8M | $-33.4M |
毛利率ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | 0.2% | ||
| Q3 25 | 43.6% | -8.3% | ||
| Q2 25 | 47.4% | -7.9% | ||
| Q1 25 | 39.5% | -25.2% | ||
| Q4 24 | 43.3% | -5.3% | ||
| Q3 24 | 44.4% | -9.6% | ||
| Q2 24 | 42.1% | -12.5% |
净利率ABCBOFIX
| Q1 26 | 35.1% | — | ||
| Q4 25 | 44.2% | -1.0% | ||
| Q3 25 | 33.7% | -11.1% | ||
| Q2 25 | 36.5% | -6.9% | ||
| Q1 25 | 30.8% | -27.4% | ||
| Q4 24 | 42.5% | -13.5% | ||
| Q3 24 | 35.0% | -13.9% | ||
| Q2 24 | 30.2% | -16.8% |
每股收益（稀释后）ABCBOFIX
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.59 | $-0.05 | ||
| Q3 25 | $1.54 | $-0.57 | ||
| Q2 25 | $1.60 | $-0.36 | ||
| Q1 25 | $1.27 | $-1.35 | ||
| Q4 24 | $1.35 | $-0.76 | ||
| Q3 24 | $1.44 | $-0.71 | ||
| Q2 24 | $1.32 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.1B | $450.0M |
| 总资产 | $28.1B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益ABCBOFIX
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.1B | $450.0M | ||
| Q3 25 | $4.0B | $442.5M | ||
| Q2 25 | $3.9B | $458.3M | ||
| Q1 25 | $3.8B | $458.3M | ||
| Q4 24 | $3.8B | $503.1M | ||
| Q3 24 | $3.7B | $525.9M | ||
| Q2 24 | $3.6B | $546.0M |
总资产ABCBOFIX
| Q1 26 | $28.1B | — | ||
| Q4 25 | $27.5B | $850.6M | ||
| Q3 25 | $27.1B | $832.6M | ||
| Q2 25 | $26.7B | $837.2M | ||
| Q1 25 | $26.5B | $823.1M | ||
| Q4 24 | $26.3B | $893.3M | ||
| Q3 24 | $26.4B | $867.9M | ||
| Q2 24 | $26.5B | $882.0M |
负债/权益比ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | $390.2M | $27.7M | ||
| Q3 25 | $104.9M | $12.4M | ||
| Q2 25 | $61.4M | $11.6M | ||
| Q1 25 | $116.9M | $-18.4M | ||
| Q4 24 | $154.2M | $23.7M | ||
| Q3 24 | $102.2M | $11.7M | ||
| Q2 24 | $-97.1M | $9.0M |
自由现金流ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | $369.6M | $16.8M | ||
| Q3 25 | $100.5M | $2.5M | ||
| Q2 25 | $53.7M | $4.5M | ||
| Q1 25 | $114.2M | $-25.1M | ||
| Q4 24 | $140.7M | $15.2M | ||
| Q3 24 | $99.8M | $6.3M | ||
| Q2 24 | $-100.3M | $-360.0K |
自由现金流率ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 120.4% | 7.6% | ||
| Q3 25 | 32.0% | 1.2% | ||
| Q2 25 | 17.9% | 2.2% | ||
| Q1 25 | 39.9% | -13.0% | ||
| Q4 24 | 48.4% | 7.0% | ||
| Q3 24 | 35.2% | 3.2% | ||
| Q2 24 | -33.4% | -0.2% |
资本支出强度ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 4.9% | ||
| Q3 25 | 1.4% | 4.8% | ||
| Q2 25 | 2.5% | 3.5% | ||
| Q1 25 | 0.9% | 3.5% | ||
| Q4 24 | 4.6% | 4.0% | ||
| Q3 24 | 0.8% | 2.7% | ||
| Q2 24 | 1.1% | 4.7% |
现金转化率ABCBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.60× | — | ||
| Q3 25 | 0.99× | — | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | -1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABCB
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
